Перспективы таргетной терапии классической лимфомы Ходжкина
Автор: Пархоменко Роман Алексеевич
Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr
Рубрика: Обзоры
Статья в выпуске: 1 т.12, 2012 года.
Бесплатный доступ
В настоящем обзоре представлены результаты ряда работ последних лет по таргентной терапии лимфомы Ходжкина. Наиболее впечатляющими можно считать результаты клинического применения препарата SGN-35 (Brentuximab vedotin - брентуксимаб ведотин, или Adcetris -адцетрис) - иммунотоксина, созданного на основе антител к CD30. Изучается возможность включения этого препарата в терапию ЛХ первой линии. Вероятно, его применение позволит уменьшить число циклов химиотерапии и/или отказаться от облучения у больных с благоприятным прогнозом. Весьма перспективными представляется применение Т-цитотоксических лимфоцитов, особенно с CCR4 и химерными рецепторами к CD30, а также панобиностата (препарата из группы инигбиторов деацетилаз гистонов).
Лимфома ходжкина, таргетная терапия
Короткий адрес: https://sciup.org/14955299
IDR: 14955299
The perspectives of targeted therapy for classical Hodgkin's lymphoma
The survey deals with the latest results of investigations on targeted therapy for classical Hodgkin’s lymphoma (cHL). The most impressive results were achieved in the clinical trials of SGN-35 (brentuximab vedotin or adcetris) - immunotoxin on the basis of anti-CD30. Now it is planned to test SGN-35 as a component of the first-line therapy. Probably the use of that drug will make it possible to reduce the number of chemotherapy cycles and to refuse from irradiation in patients with beneficial prognostic features. Among other promising modalities of targeted therapy of cHL we can also name panobinostat and cytotoxic T-lymphocites.
Список литературы Перспективы таргетной терапии классической лимфомы Ходжкина
- Younes A. N. ovel treatment strategies for patients with relapsed classical Hodgkin lymphoma.//Hematology Am Soc Hematol Educ Program. 2009. P. 507-19.
- Новик А.В. Таргетная терапия при лимфопролиферативных заболеваниях.//Практическая онкология. Т 11. № 3. 2010. С. 131-142.
- Katz J., Janik J. E., Younes A. Brentuximab Vedotin (SGN-35).//Clin Cancer Res. 2011. V. 17. N. 20. P. 6428-6436.
- Younes A. CD30-targeted antibody therapy.//Curr Opin Oncol. 2011. V. 23. N. 6. P. 587593.
- Schnell R., Dietlein M., Staak J.O. et al. Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131-Labeled Murine Anti-CD30 Monoclonal Antibody.//Journal of Clinical Oncology. 2005. Vol. 23. No 21. P. 4669-4678.
- Freedman A. S., Kuruvilla J., Assouline S. E. et al. Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592).//52 Annual Meeting of American Society of Hematology. Book of abstracts. 2010. Аbstract 284.
- Smith S. M., Bartlett N., Johnson J. L. et al. Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602. 2010 ASCO Annual Meeting.//J Clin Oncol 28: 15s, 2010 (suppl; abstr 8039).
- Kirschbaum M.H., Goldman B.H., Zain J.M. et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.//Leuk Lymphoma. 2011 Sep 19. [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/21823829
- Oki Y., Copeland A., Younes A. Clinical development of panobinostat in classical Hodgkin's lymphoma.//Expert Rev. Hematol. 2011. V. 4. N. 3. P. 245-252.
- Johnston P.B., Inwards D.J., Colgan J.P. et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.//Am. J. Hematol. 2010. V. 85. N. 5. P. 320-324.
- Younes A., Pro B., Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.//Blood. 2006. V. 107. P. 1731-1732.
- Blum K.A., Johnson J.L., Niedzwiecki D. et al. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.//Leuk. Lymphoma. 2007. V. 48. P. 1313-1319.
- Fanale M.A., Fayad L.E., Pro B. et al. A phase I study of bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma [abstract].//Blood. 2008. V. 112. P. 3048.
- Mendler J.H., Kelly J., Voci S. et al. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.//Ann. Oncol. 2008. V. 19. N. 10. P. 1759-1764.
- Sauer S., Erba P.A., Petrini M. et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients.//Blood. 2009. V. 113. N. 10. P. 2265-2274.
- Younes A., Romaguera J., Hagemeister F. et al. A pilot study of rituximab in patients with recurrent classic Hodgkin disease.//Cancer. 2003. V. 98. N. 2. P. 310-314.
- Wedgwood A.R., Fanale M.A., Fayad L.E. et al. Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy [abstract].//Blood. 2007. V. 110. P. 215.
- Fehniger T.A., Larson S., Trinkaus K. et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.//Blood. 2011. Sep 21. [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/21937701
- Bollard C.M., Aguilar L., Straathof K.C. et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease.//J. Exp. Med. 2004. V. 200. P. 1623-1633.
- Bollard C.M., Huls M.H., Buza E. et al. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.//Clin. Lymphoma Myeloma. 2006. V. 6. P. 342-347.
- Bollard C.M., Gottschalk S., Leen A.M. et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.//Blood. 2007. V. 110. P. 2838-2845.
- Di Stasi A., De Angelis B., Rooney C.M. et al. T lymphocytes co-expressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and anti-tumor activity in a Hodgkin’s tumor model.//Blood. 2009. V. 113. P. 6392-6401.
